
Evaluating NICE guidelines in regards to cannabis-based medicinal products targeting pain
Campaigners argue the new regulations are not extensive enough where the recommendation of cannabis-based medicine for pain is concerned.
ByCampaigners argue the new regulations are not extensive enough where the recommendation of cannabis-based medicine for pain is concerned.
By GlobalDataHIV infections can be well controlled with antiretroviral therapy to a degree where the viral load is not detectable…
By GlobalDataSickle cell disease comprises a group of inherited disorders caused by mutations of haemoglobin subunit beta.
By GlobalData84% of gene therapy trials happening in various neurology indications, listed in GlobalData’s Pharma Intelligence Center, are in early-stage…
By GlobalDataThe number one drug in biosimilar clinical trials by count is adalimumab biosimilar, referencing the branded biologic Humira.
By GlobalDataCurrently, the UK accounts for 16% of global cell therapy manufacturing facilities, according to GlobalData’s Contract Service Provider Database.
By GlobalData